anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To obtain a composition useful for treating cancer, containing α- ketoglutaric acid and a compound having ability to form azomethine. CONSTITUTION: This composition contains (A) α-katoglutaric acid and (B) a compound having ability to form azomethine and selected from 5- hydroxymethylfurfural, dehydroascorbid acid, maltol and vanillin in the weight ratio A/B of (2:1) to (12:1) [pref. (3:1) to (8:1)]. In preparing this composition, the system is adjusted to pH4-6 by adding an alkali except ammonia and amines to the system before, during or after mixing the component A with the component B. If a monosaccharide (esp. glucose or fructose) is added to this composition, the acidic metabolite of the monosaccharide promotes the action of the component A in malignant tumor, and furthermore, stabilization of this composition is promoted.
This utility model is directed to the extraction process of aqueous solution that contains a specified concentration of herbal substance. It specifically covers the decoction of fresh leaves and stems of Orthosiphon aristatus to collect 50 pcnt weight/volume (w/v) concentration of aqueous crude extracts which are used as herbal anthelmintic of swine. A 750 g fresh leaves and stems of O. aristatus are gathered and are tom apart into small pieces. These plant materials are thoroughly washed with clean water and drained through aluminum strainer. The drained plant materials are submerged into a vessel filled with 1500 ml clean cold water. The decoction of O. aristatus fresh stem and leaves is done for 15-20 minutes at a temperature of 100 to 110 oC. Then bring it to simmer with a lid on for another 10 to 15 minutes and then allowed to cool. After which the aqueous crude extract is filtered through clean cheese cloth on a funnel.
BACKGROUND: Primary periodic paralysis (PPP) is an inherited disorders of ion channel dysfunction characterized by recurrent episodes of flaccid muscle weakness, which can classified as hypokalemic (HypoPP), normokalemic (NormoPP), or hyperkalemic (HyperPP) according to the potassium level during the paralytic attacks. However, PPP is charactered by remarkable clinical and genetic heterogeneity, and the diagnosis of suspected patients is based on the characteristic clinical presentation then confirmed by genetic testing. At present, there are only limited cohort studies on PPP in the Chinese population.
RESULTS: We included 37 patients with a clinical diagnosis of PPP. Eleven (29.7%) patients were tested using a specific gene panel and 26 (70.3%) by the whole-exome sequencing (WES). Twenty-two cases had a genetic variant identified, representing a diagnostic rate of 59.5% (22/37). All the identified mutations were either in the SCN4A or the CACNA1S gene. The overall detection rate was comparable between the panel (54.5%: 6/11) and WES (61.5%: 16/26). The remaining patients unresolved through panel sequencing were further analyzed by WES, without the detection of any mutation. The novel atypical splicing variant c.2020-5G > A affects the normal splicing of the SCN4A mRNA, which was confirmed by minigene splicing assay. Among 21 patients with HypoPP, 15 patients were classified as HypoPP-2 with SCN4A variants, and 6 HypoPP-1 patients had CACNA1S variants.
CONCLUSIONS: Our results suggest that SCN4A alleles are the main cause in our cohort, with the remainder caused by CACNA1S alleles, which are the predominant cause in Europe and the United States. Additionally, this study identified 3 novel SCN4A and 2 novel CACNA1S variants, broadening the mutation spectrum of genes associated with PPP.
PROBLEM TO BE SOLVED: To discriminate the pollinosis symptom-relaxing action of a cosmetic by using the acidity o the cosmetic containing a powdery material as an index. SOLUTION: This method for discriminating a cosmetic for pollinosis comprises adding 4 pts.wt. of distilled water to 1 pt.wt. of the cosmetic, stirring the mixture for 30 min, and subsequently measuring the pH of the liquid portion of the mixture. When the measured pH is <=6, preferably <=5, it is discriminated that the cosmetic is effective for relaxing the symptom of the pollinosis and for preventing the crises of the pollinosis. The cosmetic applied to the discrimination method is preferably a make-up cosmetic such as a foundation or face powder which is used in the wide area of a face to form the outermost layer of cosmetic layers formed on the face.
PURPOSE: A novel Chungangia sp. CAU 8465 (KCTC 11741BP) strain with an antibacterial activity is provided to enhance antibacterial activity. CONSTITUTION: A novel Chungangia sp. CAU 98465(KCTC 11741BP) has an antibacterial activity. The strain has 16S rRNA gene sequence of sequence number 1. The strain has the antibacterial activity against Escherichia coli, Salmonella typhimurium, Bacillus subtilis, Staphylococcus aureus, or Candida albicans. An antibacterial composition contains the strain or culture thereof as an active ingredient.
AIMS: Excessive alcohol consumption leads to alcoholic liver disease (ALD), a major contributing factor to cirrhosis and hepatocellular carcinoma. In the present study we investigated the involvement of phospholipase D2 (PLD2) in the pathogenesis of ALD.
METHODS AND MATERIALS: ALD was induced in mice by chronic and binge ethanol feeding (the NIAAA model). Cellular transcriptome was examined by RNA-seq.
KEY FINDINGS: Analysis of RNA-seq datasets indicated that PLD2 expression was up-regulated in liver tissues and in hepatocytes during ALD pathogenesis. Exposure of hepatocytes to ethanol treatment led to an increase in PLD2 expression. Similarly, ethanol feeding in mice stimulated PLD2 expression in the liver. On the contrary, PLD2 knockdown in hepatocytes down-regulated expression of pro-inflammatory and pro-lipogenic genes and dampened lipid accumulation. Consistently, PLD2 knockdown in mice significantly ameliorated ALD pathogenesis as evidenced by reduced steatosis and hepatic inflamamation. RNA-seq identified several metabolic pathways that were influenced by PLD2 deficiency.
SIGNIFICANCE: Our data demonstrate that PLD2 is a novel regulator of ALD and suggest that small-molecule PLD2 inhibitors can be considered as a reasonable strategy for ALD treatment.
Immunological disorders predispose affected individuals to a myriad of complications, including infection, immune dysregulation with autoimmune disease and aberrant inflammatory responses, and malignancy. Advances in genetic testing have propelled the discovery of the genetic underpinnings of numerous immunodeficiencies. However, a more complete picture of the immune system is needed to better characterize patients that present with the signs and symptoms of immunodeficiency or immune dysregulation in whom there is no identifiable genetic diagnosis. Many of our diagnostic tools, such as characterization of cell subset frequencies, look at only one parameter in the immune system, which is typically insufficient to capture the system s complexity. Systems immunology is a field of research aimed to identify and understand how the different components of the immune system work together in a coordinated manner to achieve its functions, such as protecting against pathogens and mounting effective responses after vaccination. The goal of this study is to collect patient samples to more deeply phenotype these individuals at the molecular and cellular levels using novel technologies in order to generate hypotheses regarding disease etiologies and mechanisms in subjects with an immune disorder without complete characterization or clear genetic etiology. We also aim to validate a specific observation seen in a previous study of patients with known monogenic immunological disorders. In the long-term, hypotheses generated in this study that address clinically significant, actionable questions will be pursued as separate investigations.

This hypothesis-generating sample collection study will recruit patients with unknown or incompletely characterized immune defects and their unaffected relatives. Under this protocol, samples will be collected at the NIH Clinical Center or mailed in for analysis using systems biology approaches to generate hypotheses regarding the potential etiologies and mechanisms of these immune defects. Initially, all subjects will give a blood sample and may give additional samples including saliva, stool, and skin punch biopsies. Subjects will be enrolled for 5 years and may be asked to give additional samples based on scientific need or changes in clinical status. Findings relevant to subjects health and medical care will be returned to them and referring healthcare providers.
Pts with confirmed HER2- breast cancer will then undergo HER2-targeted PET/CT. 89Zr-trastuzumab is a novel radiotracer which allows excellent visualization of HER2+ lesions. 89Zr-pertuzumab is a novel radiotracer which may allow for specific visualization of HER2+ lesions. PET/CT imaging with these novel radiotracers will allow evaluation of all identifiable malignant lesions, rather than evaluation of only single lesions by biopsy. Avid lesions will be considered suspicious for HER2+ malignancy. Pts with at least one 89Zr-trastuzumab or 89Zr-pertuzumab avid lesion will be biopsied to confirm HER2+ pathology. From these 50 pts, we will determine the proportion of HER2- primary breast cancer pts that express HER2+ malignancy imagable by HER2-targeted PET/CT. Pts recruited to the protocol, but then drop out prior to HER2-targeted PET/CT due HER2+ disease being identified on retesting of the patient's archived tissue samples, will be replaced with newly recruited pts.
Among the most prevalent internal diseases worldwide are metabolic, respiratory and infectious diseases. Despite important progress in the field of these diseases, their frequent coexistence leads to a state of so-called fragility, now recognised as a genuine pathological condition, and entails the need to optimise their management in order to ensure faster and more effective diagnostic processes and targeted treatment procedures. On the other hand, those less frequent and less defined from both a pathogenetic and a management point of view include immune-mediated diseases, rare diseases, and internist disorders of pregnancy. Many times, diagnostic and therapeutic algorithms validated for specific diseases are arbitrarily applied to less common diseases based on the similarity of the clinical picture. For example, indices of inflammation such as C-reactive protein and erythrocyte sedimentation rate, traditionally used as markers of inflammatory response to infection, are commonly used as surrogate markers of disease activity in non-infectious immune-mediated diseases, despite the fact that there are no studies demonstrating their specific usefulness in patients suffering from them. This often leads to inappropriate care choices, as they are not based on sufficient degrees of evidence for those specific diseases. Studies focusing on specific disease categories are necessary to identify disease-specific markers and thus target therapy in an informed manner. Both the most prevalent and the least characterised pathologies require the integrated work of third-level centres, such as the San Raffaele Hospital, which have a large number of patient referrals and can therefore make a concrete contribution to the advancement of knowledge of these pathologies and their management and make their mark in the international scientific community. To this end, a prospective observational study is being conducted aimed at the detailed characterisation of patients suffering from these pathologies, in order to identify possible risk factors and markers of severity that can guide the development of new diagnostic and therapeutic strategies.
Vision loss has been associated with mental health problems such as depression, anxiety, and post-traumatic stress disorder, which significantly impact lives of working age adults with adventitious total bilateral blindness and low vision. It is imperative, therefore, to prioritize the mental health in this population by exploring and understanding the factors that impact on their mental health. Hence, the objective of this scoping review is to identify and chart existing literature on the protective and risk factors of mental health of working age adults with adventitious total bilateral blindness and low vision. We developed this scoping review protocol in line with the Joanna Briggs Institute guidance. This scoping review will include publications in English language with no date restrictions exploring the protective and risk factors of mental health of our study population. A three-step search strategy will be employed. Searches will be carried out in the following databases: Medline, Embase, PsycInfo, PsycArticles, CINAHL and Web of Science. Search for grey literature will be conducted in Google, Google Scholar and Websites dedicated to information on visual impairment. Collated results will be imported into Endnote Basic (Clarivate) for deduplication. Two reviewers will independently conduct double screening of all the titles and abstracts in Rayyan- a web application, and full texts in Endnote while three other reviewers will conduct screening of a subset of for example 10% of titles and abstracts and full texts. Furthermore, two reviewers will independently conduct double data extraction while three other reviewers will revise, cross check, and correct any extraction errors. Extracted data will be presented in tabular formats and summarized descriptively in line with the research objectives. This scoping review will generate evidence on factors impacting the mental health of the working age adults with adventitious total bilateral blindness and low vision as well as critically highlight gaps in the literature. The findings will inform and critically underpin future empirical research which will explore the lived experiences of working age people with adventitious total bilateral blindness. Additionally, evidence from this review will inform the development of interventions in the promotion of mental health as well as assisting rehabilitation specialists and workers, public health practitioners and other relevant stakeholders in addressing the mental health needs of working age adults with adventitious total bilateral blindness and low vision.
BACKGROUND: We recently conducted a phase 2 trial (NCT028865685) evaluating intracranial efficacy of pembrolizumab for brain metastases (BM) of diverse histologies. Our study met its primary efficacy endpoint and illustrates that pembrolizumab exerts promising activity in a select group of patients with BM. Given the importance of aberrant vasculature in mediating immunosuppression, we explored the relationship between immune checkpoint inhibitor (ICI) efficacy and vascular architecture in the hopes of identifying potential mechanisms of intracranial ICI response or resistance for BM.
METHODS: Using Vessel Architectural Imaging, a histologically validated quantitative metric for in vivo tumor vascular physiology, we analyzed dual-echo DSC/DCE MRI for 44 patients on trial. Tumor and peri-tumor cerebral blood volume/flow, vessel size, arterial and venous dominance, and vascular permeability were measured before and after treatment with pembrolizumab.
RESULTS: BM that progressed on ICI were characterized by a highly aberrant vasculature dominated by large-caliber vessels. In contrast, ICI-responsive BM possessed a more structurally balanced vasculature consisting of both small and large vessels, and there was a trend toward a decrease in under-perfused tissue, suggesting a reversal of the negative effects of hypoxia. In the peri-tumor region, the development of smaller blood vessels, consistent with neo-angiogenesis, was associated with tumor growth before radiographic evidence of contrast enhancement on anatomical MRI.
CONCLUSIONS: This study, one of the largest functional imaging studies for BM, suggests that vascular architecture is linked with ICI efficacy. Studies identifying modulators of vascular architecture, and effects on immune activity, are warranted and may inform future combination treatments.
<P>PROBLEM TO BE SOLVED: To provide a diagnostic system which makes a work flow in a facility efficient in small-scale facilities.  <P>SOLUTION: According to the small-scale diagnostic system 1, when a patient who visits a doctor's office is registered at a receipt computer 5 at a reception desk, a patient information list of patients who visit the doctor's office on the day is created, and a screen of a patient list is displayed on a display part 221 of a reading device 202. When the patient's information of the patient subjected to imaging is specified from the screen of the patient list of the reading device 202, and a cassette is mounted, a bar code labeled on the cassette is read out, and cassette information (plate type information and cassette size information) expressed by the bar code is acquired. Then, the acquired information with a cassette mounting notification and the specified patient's information is transmitted to the receipt computer 5. In the receipt computer 5, receipt-related information of the specified patient is created based on the information received from the reading device 202.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Participants will receive an SC injection of TV-46000 at baseline and every 8 weeks (q8w) thereafter, and a placebo SC injection 4 weeks after baseline and q8w thereafter. The maximal dose for adult participants is comparable to an oral risperidone dose of 5 mg/day, and the maximal dose for adolescents is comparable to 4 mg/day. Participants will continue treatment until they experience a relapse event; meet 1 or more of the study discontinuation or withdrawal criteria; or remain relapse-free during the double-blind phase until the study is terminated.
Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks. Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of semaglutide or of other semaglutide products.

During the 68-week treatment periods in Studies 2 and 3 [see Clinical Studies (14.2)], 50/1709 (3%) of WEGOVY-treated patients developed anti-semaglutide antibodies. Of these 50 WEGOVY-treated patients, 28 patients (2% of the total WEGOVY-treated study population) developed antibodies that cross-reacted with native GLP-1. No identified clinically significant effect of anti-semaglutide antibodies on pharmacokinetics for WEGOVY was observed. There is insufficient evidence to characterize the effects of anti-semaglutide antibodies on pharmacodynamics or effectiveness of semaglutide.
The present invention relates to the fields of life sciences and food, feed or pharmaceutical industry. Specifically, the invention relates to novel peptides, pilus structures, polynucleotides as well as vectors, host cells, products and pharmaceutical compositions comprising the polynucleotides, peptides or pilus structures. The invention also relates to gene clusters and antibodies. Furthermore, the present invention relates to methods for producing the peptides or pilus structures or producing the products comprising the peptides or pilus structures. Furthermore, the present invention relates to treatments as well as uses and methods for screening bacterial strains, for reducing or inhibiting the adhesion of pathogenic bacteria, promoting the adhesion of bacterial cells to the mucus and for modifying immune response in a subject.; Still, the present invention relates to methods for detecting probiotic bacterial strains or pathogen strains.
Ablative stereotactic radiation on the metastatic sites. Delivered in a 1 to 5 fractions regimen.
The nucleus of Cephalosporin C, Cephalosporin Cc or a Cephalosporin Ca compound is prepared by treating Cephalosporin C, Cephalosporin Cc or a Cephalosporin Ca compound, such as Cephalosporin Ca (pyridine), or a derivative of any of these compounds in which the amino group of the amino-adipoyl sidechain is blocked by a grouping which is not detached therefrom during the hydrolysis and which hinders Zwitterion formation in the sidechain, with acid under such conditions and for such a time that cleavage of the sidechain or blocked sidechain from the nucleus occurs to form the corresponding nucleus and separating the nucleus so formed from the reaction products.  The blocking group may be 2,4-dinitrophenyl or 2-nitro-4-carbomethoxyphenyl and the preferred acid is hydrochloric acid.  Other acids which may be used include sulphonic acids and sulphonated polystyrene resins.  The nucleus may be separated from the reaction products by electrophoresis, chromatography or ion exchange. The nucleus of Cephalosporin C forms salts, such as sodium, potassium and ammonium salts, on bases, and all three types of nuclei form acid addition salts at the primary amino group. The nuclei may be used in the production of new Cephalosporins by acylation of the 7-amino group. Specifications 810,196, 912,360 and 912,541 also are referred to.
PCT No. PCT/US93/04179 Sec. 371 Date Dec. 28, 1994 Sec. 102(e) Date Dec. 28, 1994 PCT Filed May 3, 1993 PCT Pub. No. WO93/22343 PCT Pub. Date Nov. 11, 1993A multiple antigenic peptide system is disclosed that comprises a dendritic core and peptide and a lipophilic anchoring moiety. This particular combination has as an advantage that it eliminates the need for the inclusion of adjuvants found to be toxic to humans, and facilitates the exponential amplification of the antigenic potential of a vaccine prepared therefrom, as noncovalent amplification by a liposome or micellar form is possible. Further, multiple different antigenic peptides may be attached so that the system may be prepared for administration to concurrently treat diverse ailments, such as for example, AIDS and influenza. The present multiple antigen peptide system is capable of eliciting an immune response when injected into a mammal, and accordingly, vaccines prepared from the system and methods of use including therapeutic protocols are included.
Therapists will work with families for 10 sessions, twice weekly. The first treatment session will be a 90 minute parent only psychoeducation and treatment preparation session. Each subsequent session will last up to 60 minutes and will consist of exposure therapy using developmentally appropriate modulated behavioral approaches such as Participant modeling (PM) and Reinforced practice (RP).